Sign in

    Ruili Bian

    Vice President and Equity Analyst at Citi

    Ruili Bian is a Vice President and Equity Analyst at Citi, specializing in the pharmaceutical and healthcare sectors, with direct coverage of companies such as Guangzhou Baiyunshan Pharmaceutical Holdings. She has published investment ratings on major Chinese pharmaceutical firms, and her performance metrics on platforms like TipRanks show a success rate of 0% on one rating, with an average return of -5.7%. Bian started her professional career as a registered representative in Hong Kong in April 2020 and has been with Citigroup Global Markets Asia Limited since then, maintaining active securities licensing with the SFC. Her credentials include multiple periods of registration as an SFC licensee, reflecting her compliance and expertise in regulated equity research.

    Ruili Bian's questions to 111 (YI) leadership

    Ruili Bian's questions to 111 (YI) leadership • Q2 2024

    Question

    Inquired about the strategy to increase penetration among pharmacy clients facing operating pressure, whether profitability is prioritized over revenue growth, and the operational impact of retail drug price comparison policies.

    Answer

    The company sees the challenges faced by offline pharmacies as an opportunity to provide support and increase wallet share. Profitability is the main priority for 2024, achieved by optimizing product selection to create a one-stop shop. To address price comparisons, the company has made low prices a core operational strategy. They also see long-term growth opportunities from the increasing number of pharmacies and the shift of drug sales from hospitals to retail due to the anti-corruption campaign.

    Ask Fintool Equity Research AI